Addressing Vaccine Hesitancy in Infectious Disease Prevention

2025 PTCE Specialty Pharmacy Day of Education in partnership with Asembia

Program Description

Vaccine hesitancy remains a significant public health challenge, affecting immunization rates across all age groups and contributing to preventable disease outbreaks. Despite strong evidence supporting the safety and efficacy of vaccines, misinformation, health care disparities, and systemic barriers continue to erode public confidence and limit access to vaccines, particularly in underserved populations. In this panel discussion, expert speakers will explore strategies to overcome vaccine hesitancy through evidence-based practices, highlight the role of pharmacists in supporting recommendations from the Centers for Disease Control and Prevention and the Advisory Committee on Immunization Practices across the lifespan, and examine how immunization policies are developed and implemented. Attendees will gain practical insights to help drive vaccine confidence and improve uptake in both pediatric and adult patient populations.

Target audience: Ambulatory Care Pharmacist, Community Pharmacist, Health System Pharmacist

Type of activity: Application

Release date: October 30, 2025

Expiration date: October 30, 2026

Time to complete activity: 1.5 hours

Learner level: Foundational, Intermediate

Fee: Free

Educational Objectives

At the completion of this activity, participants will be able to:

• Explore the importance of providing lifespan immunization against vaccine-preventable diseases to reduce morbidity and mortality
• Explain the barriers and health care disparities associated with vaccine uptake across different patient populations
• Identify the pharmacist’s role in improving vaccine uptake through awareness of best practices, policies, and strategies that support CDC recommendations

Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.5contact hours (0.15 CEU) under the ACPE universal activity number 0290-0000-25-347-H06-P. The activity is available for CE credit through October 30, 2026.

Instructions for Completing the Activity and Receiving CPE Credit

To receive CPE credit, participants must complete the pretest, review the activity in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.

Disclosures

Carrie Foust Koenigsfeld, PharmD., FAPhA , has the following financial relationships with commercial interests to disclose:
Speaker's Bureau: GSK, Pfizer

James D. Lewis II, PharmD, FIDSA has the following financial relationships with commercial interests to disclose:

Consultant: Selux Diagnostics, Merch, Shionogi, Innoviva, Meitheal, Melinta

The following contributors have no relevant financial relationships with commercial interests to disclose:

Faculty

Randy P. McDonough, PharmD, MS, BCGP, BCPS, FAPhA , Deanna Tran, PharmD, BCACP, FAPhA

Pharmacy Times Continuing Education^™ Planning Staff—Jim Palatine, RPh, MBA; Liza Patel, PharmD, RPh; Kylie Ferrentino; Susan Pordon; Brianna Winters; and Chloe Taccetta have no relevant financial relationships with commercial interests to disclose.

At least one anonymous peer reviewer was used as part of content validation and conflict resolution. The peer reviewer has no relevant financial relationships with commercial interests to disclose.

Educational Disclaimer

CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.

For questions about this internet CPE activity, please contact:
ceinfo@pharmacytimes.com
Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms